Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenacapavir (GS-6207) SC in HIV-1
NCT03739866Phase 1Completed
- Sponsor
- Gilead Sciences
- Start
- Nov 2018
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of lenacapavir in human immunodeficiency virus type 1 infection (HIV-1) (8 arms), sponsored by Gilead Sciences. Primary endpoint: Maximum Reduction in Plasma HIV-1 RNA. Started Nov 2018; status: completed.
02
Drugs
lenacapavir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT03739866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03739866.